Description
Background:
Abituzumab is a chimeric IgG2 monoclonal antibody targeted at CD51 (an integrin) currently under development for prevention of bone lesion metastases in castration-resistant prostate cancer. It includes the antigen binding sites of the anti-integrin mouse antibody 17E6 and binds to and inhibits the activity of alphaVbeta3 integrin (vitronectin receptor). This results in the inhibition of endothelial cell-cell interactions, endothelial cell-matrix interactions, and integrin-mediated tumor angiogenesis and metastasis in alphavbeta3-expressing tumor cells.
Intended Use:
For Estimation of Abituzumab in human serum and plasma. Please note the kit has not been optimized to be used for any other animal species. Should you require a specific sera tested, please connect with us at sales@krishgen.com for optimization.
Principle:
The method employs the quantitative sandwich enzyme immunoassay technique. Antibodies to Abituzumab are pre-coated onto microwells. Samples and standards are pipetted into microwells and human Abituzumab present in the sample are bound by the capture antibody. Then, a HRP (horseradish peroxidase) conjugated anti-Abituzumab antibody is pipetted and incubated. After washing microwells in order to remove any non-specific binding, the ready to use substrate solution (TMB) is added to microwells and color develops proportionally to the amount of Abituzumab in the sample. Color development is then stopped by addition of stop solution. Absorbance is measured at 450 nm.
If you have published a paper by using any of our ELISA since 01/01/2023, kindly fill out the “Krishgen Publication Reward Application Form” with complete information and send it by at email: info@krishgen.com, with the subject “Krishgen Publication Reward”. We will get back to you with the Amazon / Krishgen Credit Reward after we confirm it ASAP!